In this #article with Pharm Tech, Dr. Asma Patel, VP of Integrated Development Services, speaks on the growing need for patient centricity, as #pediatric patients as require age-appropriate and palatable dosage forms. Read more here: https://bit.ly/4g5eMku
Quotient Sciences
Pharmaceutical Manufacturing
Nottingham, Nottinghamshire 19,412 followers
Molecule to cure. Fast.
About us
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast. Because humanity needs solutions, fast. We employ over 1,300+ staff and operate from state-of-the-art manufacturing and clinical facilities in the US and UK. Our people make Quotient Sciences a special place to work. We are a dedicated team passionate about innovating and transforming drug development to help our customers develop new medicines for patients in need. We recruit people that are committed to making a difference, who excel at customer service and are always willing to go the extra mile. Teamwork is integral to our culture and success — helping, supporting and mentoring run through our DNA. Expect to join an empowering and innovative culture, where we encourage continuous improvement and offer opportunities to learn and develop every day.
- Website
-
https://bit.ly/3u9sI6l
External link for Quotient Sciences
- Industry
- Pharmaceutical Manufacturing
- Company size
- 1,001-5,000 employees
- Headquarters
- Nottingham, Nottinghamshire
- Type
- Privately Held
- Specialties
- CDMO, Formulation Development, Phase I & II Clinical Trial Manufacturing, Translational Pharmaceutics, High Potency Handling, Real-time Adaptive Manufacturing, Commercial Manufacturing, Solubility Enhancement, Modified Release, Pediatric Formulation Development, CRO, First-in-Human, Clinical Pharmacology, Relative Bioavailability, Pharmacokinetics, Drug-Drug Interaction, Human ADME / 14C, Data Sciences, Modelling & Simulation, Drug Substance, Scintigraphy, Bioanalysis, Isotope Labelling, Clinical Trial Supplies, Bioequivalence, Healthy Volunteer Studies, Proof-of-Concept, Drug Development, and Dosage Form Development
Products
Locations
Employees at Quotient Sciences
Updates
-
#ICYMI: In our latest #webinar, Dr. Andy Lewis, Chief Scientific Officer, and Dr. Stuart Mair, Chief Medical Officer, explore the latest developments and future innovations in orally- delivered #GLP1 agonists. 💻 ▶️ Watch the recording: https://bit.ly/3WEKa0j
-
-
In this article with Thierry Van Nieuwenhove, we discuss the company's essential role in helping our customers innovate their drug programs as a trusted #CDMO & #CRO services partner:
-
What are you looking for when seeking support for your program? Check out our newly updated #website to learn more about our service offerings and how we can help you overcome the challenges you're facing. https://bit.ly/3Mm5HpW
-
#ICYMI: In this feature with Drug Development & Delivery, Andy Lewis, Chief Scientific Officer, discusses on our #TranslationalPharmaceutics® platform and its benefits, including the potential to accelerate and control the full #drugdevelopment value chain. Read the full article here: https://bit.ly/4bqABaj
Unlocking True Partnerships: Going Beyond Science in Outsourcing Formulation Development & Manufacturing
quotientsciences.com
-
Hear from Dr. Asma Patel, VP of Integrated Development Services, in this #blog focused on #CMC challenges often faced when developing life-saving treatments and discover more about strategies to mitigate CMC risks. Read here: https://bit.ly/3LYwFmU
-
-
A day in the life at Quotient Sciences: Get a peek into life at our company from colleagues in our Project Management and Clinical Operations teams. Read their stories: https://bit.ly/3IQvZ1o
-
-
Martin Wing-King, Vice President and General Manager, Site Head at #QuotientSciences Reading, discusses the demand for accelerated pathways to first-in-human (FiH) trials, along with the team's experience and capabilities offered on-site at our Reading facility: https://bit.ly/45woQOx
-
-
John McDermott, VP of Scientific Consulting, explains how our innovative #TranslationalPharmaceutics® platform can maximize efficiency, allowing for the reduction of batch sizes and more flexibility in studies, reducing timelines and saving costs. Learn more about how our services can help advance your next project: https://bit.ly/3WpYACe
-
Join us for our upcoming #seminar this October in Belmont, CA. Led by Dr. Vanessa Zann, Executive Drug Development Consultant, this event will focus on how the integration of GMP manufacturing and clinical testing via #TranslationalPharmaceutics® can accelerate #drugdevelopment and will offer the chance to develop a better understanding of its application to #RapidFACT®. Register today: https://bit.ly/3SD9r9Q
This content isn’t available here
Access this content and more in the LinkedIn app